Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma
Status:
Recruiting
Trial end date:
2023-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether new metabolic imaging will be useful to
physicians and patients with glioblastoma for making treatment decisions and seeing how well
various types of treatment work. The goal is to improve the way patient care is managed in
the future.
If you chose to be in this study, you will be receiving novel magnetic resonance (MR)
metabolic imaging with standard MR imaging. The research component includes an injection of
an investigational agent, called hyperpolarized 13C pyruvate, to obtain dynamic metabolic
imaging.